

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 01-2-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 07-10-2006 TO BE PUBLISHED ON 02-1-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1305/2006	<u>02-10-2006</u> DyStar Textilfarben GmbH & Co. Deutschland KG, Germany (Priority 05-10-2005 Germany)	“Azo reactive dyes and mixtures of fiber-reactive azo dyes, their preparation and their use”
1306/2006	Tanabe Seiyaku Co. Ltd., Japan (Priority 09-01-2003 Japan) DIVISIONAL	“A pharmaceutically acceptable salt of a condensed furan compound as an inhibitor of activated blood coagulation factor”
1307/2006	Aventis Pharmaceuticals Inc., USA (Priority 04-10-2005 USA)	“Pyrimidine amide compounds as pgds inhibitors”
1308/2006	Otsuka Pharmaceutical Co. Ltd., Japan (Priority 11-10-2002 Japan)	“A pharmaceutically acceptable salt of a 2, 3-dihydro-6-nitroimidazo[2, 1-b]oxazole compound having bactericidal action against mycobacterium tuberculosis, multi-drug-resistant mycobacterium tuberculosis, and atypical acid-fast bacteria”
1309/2006	Dow Corning Taiwan Inc., Republic of China (Priority 04-10-2005 GB)	“Liquisidsilicone rubber composition for textile coating”
1310/2006	Bayer HealthCare AG, Germany (Priority 04-10-2005 Germany)	“Solid pharmaceutical dosage forms which can be administered orally and have rapid release of active ingredient”
1311/2006	<u>03-10-2006</u> Bayer Corpscience AG, Germany (Priority 19-10-2005 Germany)	“Tube or bottle-like container”
1312/2006	Novartis AG, Switzerland	“Pharmaceutically active thtrahydro-pyrrolizinone compounds”

(Priority 06-10-2005 UK)

1313/2006	Glaxo Group Limited, United Kingdom (Priority 21-08-2002 GB) DIVISIONAL	“A Pharmaceutically acceptable derivative of a pyrimidine compound and a pharmaceutical composition comprising thereof”
1314/2006	Otsuka Pharmaceutical Co, Ltd., Japan (Priority 05-10-2005 Japan)	“Pharmaceutical Composition”
1315/2006	Neuralab Limited, and Wyeth Wyeth U.S.A. (Priority 12-03-2002 USA) DIVISIONAL	“Humanized antibody that recognized beta amyloid peptide”
1316/2006	AstraZeneca AB, Sweden (Priority 03-10-2005 Sweden)	“New Compounds”
1317/2006	Wyeth U.S.A. (Priority 30-07-2003 USA) DIVISIONAL	“Pharmaceutically acceptable salts of 3-amino chroman derivatives for treatment of serotonin disorders”
1318/2006	Wyeth U.S.A. (Priority 30-07-2003 USA) DIVISIONAL	“2-Amino tetralin derivatives useful in the treatment of serotonin disorders”
1319/2006	Wyeth U.S.A. Priority 30-07-2003 USA) DIVISIONAL	“Pharmaceutically acceptable salts of 2-amino tetralin derivatives useful in the treatment of serotonin disorders”
1320/2006	1. Sanofi, France 2. Akzo Nobel NV, Netherlands (Priority 19-01-1998 France) DIVISIONAL	“Pharmaceutically acceptable salts of novel synthetic hexadecasaccharides, process for their preparation and pharmaceutical compositions containing them”
1321/2006	Glaxo Group Limited,	“Pharmaceutically acceptable salts of


	UK (Priority 17-10-99 UK) DIVISIONAL	novel piperazine compound, process for their preparation and compositions containing them”
	<u>04-10-2006</u>	
1322/2006	Chinoín Gyógyszer és Vegyeszeti Termékek Gyára Rt. Hungary (Priority 05-10-05 Hungary)	“Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules”
1323/2006	1. Muhammad Rauf, 2. S. Abdul Ali, 3. Muhammad Adil and 4. Askari Begum PCSIR Laboratories, Karachi.	“A process for the production of green Chilli Powder”
1324/2006	1. Mr. Muhammad Rauf, 2. Nargis Sabah, 3. Mr. Muhammad Adil and 4. Askari Begum PCSIR Laboratories, Karachi.	“A process for the preservation of falsa fruit in powder form and production of instant falsa drink”
1325/2006	Theravance, Inc., U.S.A. (Priority 13-11-2002 USA)	“A rylaniline B2 Adrenergic receptor agonists”
1326/2006	Merck & Co. Inc., U.S.A. (Priority 13-10-2005 US)	“Acyl indoles, Compositions containing such compounds and methods of Use”
1327/2006	Sanofi-Aventis Deutschland GmbH. Germany (Priority 06-10-2005 EP)	“N-(1,3,4)-Thiadiazol-2-Yl-Benzene sulfonamides, processes for their preparation and their use as pharmaceuticals”
1328/2006	Sanofi-Aventis Deutschland GmbH. Germany (Priority 06-10-2005 EP)	“Cyclic N-[1,3,4]-Thiadiazol-2-Yl-Benzene Sulfonamides, processes for their preparation and their use as pharmaceuticals”
1329/2006	Targacept, Inc., U.S.A.	“A pharmaceutically acceptable salt of an arylvinylazacycloalkane

	(Priority 05-03-2003 US) DIVISIONAL	compound, method of its preparation and a pharmaceutical composition comprising thereof”
1330/2006	Sanofi-Aventis Deutschland GmbH. Germany (Priority 06-10-2005 EP)	“2-Amino-indan-5-sulfonic acid [1,3,4]-thiadiazol-2-Yl-Amides, processes for their preparation and their use as pharmaceuticals”
1331/2006	Sanofi-Aventis Deutschland GmbH. Germany (Priority 06-10-2005 EP)	“4-Oxy-N-(1,2,4)-Thiadiazol-2-Yl-Benzene sulfonamides, processes for their preparation and their use as pharmaceuticals”
1332/2006	Bristol-Myers Squibb Company, U.S.A. DIVISIONAL	“A nontoxic pharmaceutically acceptable salt of 3-substituted-4-arylquinolin-2-one compound as potassium channel modulator”
	<u>05-10-2006</u>	
1333/2006	AstraZeneca AB, Sweden Priority 06-10-2005 GB)	“Novel Compound”
1334/2006	Biotempt B.V. Netherlands	“Oligopeptides for reducing elevated blood urea concentration”
1335/2006	Pfizer Products Inc., U.S.A. (Priority 07-10-2005 (USA)	“Inhibitors of the HIV Integrase Enzyme”
1336/2006	Clariant International Ltd., Switzerland (Priority 07-10-2005 EP)	“Dyeing of wool fibres”
1337/2006	Clariant International Ltd. Switzerland (Priority 07-10-2005 EP)	“Dyeing of polyamide fibres”
1338/2006	Wyeth U.S.A. (Priority 05-10-2005 USA)	“Process for the synthesis of progesterone receptor modulators”
1339/2006	Almirall Prodesfarma, SA, Spain	“New imidazopyridine derivatives”

(Priority 05-10-2005 Spain)

1340/2006	1.Bioceres SA, 2.Consejo Nacional De, Argentina (Priority 29-03-2006 Argentina)	“DNA constructions that contain Helianthus annuus Hahb-10 gene coding sequence, method for generating plants with a shortened life cycle and a high tolerance to herbicidal compounds and transgenic plants with that sequence”
1341/2006	<u>06-10-2006</u> Wold wide Stationery Manufacturing Company Ltd., Hong Kong (Priority 24-03-2006 US)	“Ring Binder Having A Clip”
1342/2006	<u>07-10-2006</u> Syngenta Participations AG., Switzerland (Priority 23-12-1997 Swiss) DIVISIONAL	“A method of controlling pests with a macrolide compound “
1343/2006	Glaxo Group Ltd., United Kingdom (Priority 10-10-2005 GB)	“Novel Compounds”
1344/2006	Glaxo Group Ltd., United Kingdom (Priority 10-10-2005 GB)	“Novel Compounds”
1345/2006	F.Hoffmann La Roche AG., Switzerland (Priority 18-01-1999 EP) DIVISIONAL	“A salt of novel hetertocyclic sulfonamide”
1346/2006	F.Hoffmann La Roche AG. Switzerland (Priority 18-01-1999 EP) DIVISIONAL	“Ester of novel heterocyclic sulfonamide”
1347/2006	Glaxo Group Ltd. UK (Priority 17-10-2000 (UK)) DIVISIONAL	“Salt of piperidine compound”
1348/2006	Glaxo Group Limited,	“Pharmaceutically acceptable salts of

	United Kingdom (Priority 14-09-2001 GB) DIVISIONAL	phenethanolamine compound, process of their preparation and composition containing them, for use in medicine”
1349/2006	Glaxo Group Limited, United Kingdom (Priority 14-02-2001 GB) DIVISIONAL	“Pharmaceutically acceptable salts of phenethanolamine compound for use in medicine”
1350/2006	Boehringer Ingelheim International GmbH., Germany (Priority 10-10-2005 EP)	“Aerosol formulations for the inhalation of beta-agonists”
1351/2006	Tetra Ural Holdings & Finance S.A., Pully (Priority 05-10-2005 Sweden)	“Method in a packaging machine”
1352/2006	Glenmark Pharmaceuticals S.A, Switzerland (Priority 07-10-2005 India)	“Substituted benzofused derivatives and their use as vanilloid receptor ligands”



SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139097	Wyeth, USA	689/2004
139098	Honda Motor Co., Ltd., Japan	692/2004
139099	Symphogern A/S, Denmark	693/2004

139100	Freepower Ltd., UK	696/2004
139101	Freepower Ltd., UK	720/2004
139102	Freepower Ltd., UK	727/2004
139103	1. Wyeth, USA 2. Board of Regents, USA	729/2004
139104	Honda Motor Co. Ltd., Japan	743/2004
139105	Alizyme Therapeutics Limited, UK	744/2004
139106	Methanol Casale S.A., Switzerland	747/2004
139107	1. Warner-Lambert Company LLC., 2. Abgenix Inc., USA	829/2004
139108	AuVitronics Ltd., Karachi, Pakistan	858/2004
139109	Unilever Plc, England	1014/2004
139110	Shell Internationale Research Maatschappij B.V., The Netherlands	1039/2004
139111	Unilever Plc, England	1042/2004

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488